<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03996941</url>
  </required_header>
  <id_info>
    <org_study_id>BCP-FTD-2019-01</org_study_id>
    <nct_id>NCT03996941</nct_id>
  </id_info>
  <brief_title>Harm Reduction Program For Informal PrEP Users In A Community-based Setting (seguiPrEP)</brief_title>
  <acronym>seguiPrEP</acronym>
  <official_title>Harm Reduction Program For Informal PrEP Users In A Community-based Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BCN Checkpoint</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Projecte dels NOMS-Hispanosida (BCN Checkpoint and BCN PrEP路Point)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundacio Lluita Contra la SIDA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BCN Checkpoint</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pre-Exposure Prophylaxis (PrEP) is a biomedical strategy consisting of the use of
      antiretroviral therapy by HIV-seronegative people at high risk of acquiring HIV, to prevent
      the infection. Many controlled and randomized clinical trials, as well as implementation
      projects have shown that the use of tenofovir disoproxil (TDF) and emtricitabine (FTC) is
      both safe and effective in the prevention of HIV infection.

      However, the administrative situation of PrEP in Spain is anomalous. Unlike in some European
      countries, PrEP is not available within the National Health System (SNS), although being
      available for the treatment of HIV infection. In Spain the fixed-dose combination of FTC /
      TDF is for hospital use only, which requires prescription by HIV specialists exclusively and
      restricts its dispensation to pharmacy services within the hospital.

      This limitation in access and the knowledge of its prevention capacity of PrEP by vulnerable
      population has led them to obtain &quot;generic FTC / TDF&quot; outside the standardized health care
      system. According to a survey conducted in Europe to characterize MSM users of PrEP carried
      out in 2016, 5% of PrEP users had acquired it on their own. Of these 70% stated they were not
      included in any regular follow-up program while using the medication. Despite the growing
      demand, there are no health programs (including information, counseling, systematic screening
      for sexually transmissible infection (STI), etc.) aimed at meeting the health care needs of
      those who already use or wish to use PrEP, neither by public nor private healthcare
      providers. This type of service is especially necessary when considering that, among PrEP
      users, one may have already an established HIV infection, theoretical increase of other STI
      and a lack of monitoring kidney functions..

      BCN Checkpoint is a community center since 2006 for the detection of HIV and other STI aimed
      at gay men, other men who have sex with men (MSM) and transgender women (TGW), which has
      shown high efficiency in HIV screening and fast referral to standard HIV care and treatment..
      In 2017 the organization opened BCN PrEP路Point, a community centre with the goal to provide
      information, to conduct clinical trials and clinical monitoring of informal PrEP use.

      For this reason, it is presented here the protocol of the SeguiPrEP study, prospective,
      longitudinal study of health care in the community environment, to MSM and TGW, users of
      informal PrEP, based on point-of-care testing technology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Catalonia 62% of new HIV diagnoses were reported in MSM in 2017. In the decade 2007-2016
      in this population group an increase in the number of HIV cases of approximately 44%. The
      knowledge, interest and willingness to use PrEP is high among MSM at higher risk of HIV
      acquisition. BCN Checkpoint was accountable for the detection of one third of all new HIV
      cases in MSM and TGW in Catalonia.

      Research hypothesis is that offering a risk reduction program, including the provision of
      health monitoring, in a community setting for informal PrEP users is justified and feasible,
      and will afford these users the possibility of using it safely. It is expected that the use
      of informal PrEP, along with HIV and other STIs screening, STI treatment, and immediate HIV
      referral to care and treatment will contribute significantly to a reduction of HIV incidence.

      This study aims to contribute to increase the body of evidence on the incidence and of
      context specific HIV management and inform policy makers on potential preventive strategies
      against the epidemic.

      AIMS

      The primary aim of the study is:

      To describe the incidence of HIV and other STIs during the study period.

      The specific aims of the study are:

      To provide harm reduction through clinical follow-up for informal PrEP users. To describe the
      conditions of informal use and acquisition of PrEP. To evaluate the effectiveness and safety
      of informal PrEP. To describe the demographic, clinical, risk factors for HIV and other STIs
      of informal PrEP users.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of HIV and other STIs during the study period.</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of people / visits = Number of visits / people who attend any visit</measure>
    <time_frame>36 months</time_frame>
    <description>This indicator will be calculated for both the number of visits and the number of people.
Disaggregation: based on sociodemographic characteristics and type of visit and PrEP guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retention percentage in the program</measure>
    <time_frame>36 months</time_frame>
    <description>% retention in the program = (People who complete the study as per protocol) / (People enrolled) x100 Disaggregation: based on sociodemographic characteristics, presence of other STIs, use of drugs and number of sexual partners.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of medicines-related problems</measure>
    <time_frame>36 months</time_frame>
    <description>Number of problems = Number of medicines-related problems Disaggregation:based on type of problem as per protocol, sociodemographic characteristics, use of drugs, medication, way of acquisition and other relevant factors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of negative results of the medication</measure>
    <time_frame>36 months</time_frame>
    <description>Number of negative results of the medication = Number of negative results of the medication Disaggregation: based on type of negative result as per protocol, sociodemographic characteristics, drug use, medication, way of acquisition and other relevant factors</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">900</enrollment>
  <condition>HIV/AIDS</condition>
  <condition>HIV Infections</condition>
  <condition>Sexually Transmitted Diseases</condition>
  <condition>Vaccination</condition>
  <condition>Adherence, Medication</condition>
  <condition>Side Effect of Drug</condition>
  <condition>Preexposure Prophylaxis</condition>
  <arm_group>
    <arm_group_label>seguiPrEP</arm_group_label>
    <description>MSM and TGW using or willing to use PrEP informally will be followed in a prospective cohort to describe safety and efficacy, and to provide them with the necessary clinical controls for using it in a safe manner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Harm reduction of informal PrEP use</intervention_name>
    <description>Users attending the study center interested in PrEP use , as well as those who could benefit from it are invited to attend an information session in which issues are touched like the effectiveness and safety of PrEP, and the characteristics of the SeguiPrEP program. This program consists of periodic clinical controls (five during the first year and four in the following period) that include: physical examination, HIV and other STI screening, control of renal functions, estimation and promotion of PrEP adherence, monitoring of adverse events associated with PrEP and counseling.
Those who decide to use PrEP or who are already using PrEP are asked to schedule an initiation visit.</description>
    <arm_group_label>seguiPrEP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PrEP follow up based on point of care testing</intervention_name>
    <description>The study center has a point-of-care technology based laboratory, which allows obtaining immediate results in order to reduce the loss of follow-up.</description>
    <arm_group_label>seguiPrEP</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Potential participants will be those who report using or intend to use PrEP, attending the
        community centers on a regular or spontaneous basis. Potential participants may be
        recruited for the study if they meet all inclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 yo at the time of the enrollment in the study.

          -  Accept voluntarily participation through signing informed consent, once explained its
             characteristics.

          -  Have obtained recently (less than 1 month) a negative result in the combined
             antigen/antibody rapid test / 4th generation ELISA or PCR HIV test.

          -  Active user or intending to use informal PrEP.

        Exclusion Criteria:

          -  People with known HIV diagnosis.

          -  Absolute contraindication (eg known hypersensitivity to the active ingredients FTC or
             TDF) of the use of PrEP.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Study is addressed to men who have sex with men and transgender women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pep Coll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundaci贸n Lucha contra el Sida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pep Coll, MD</last_name>
    <phone>933182056</phone>
    <email>info@hispanosida.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>BCN Checkpoint</name>
      <address>
        <city>Barcelona</city>
        <zip>08015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>933182056</phone>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.bcncheckpoint.com/</url>
    <description>website of BCN Checkpoint</description>
  </link>
  <link>
    <url>https://www.flsida.org/es</url>
    <description>website of Fundaci贸n Lucha contra el Sida</description>
  </link>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 17, 2019</study_first_submitted>
  <study_first_submitted_qc>June 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2019</study_first_posted>
  <last_update_submitted>July 6, 2019</last_update_submitted>
  <last_update_submitted_qc>July 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PrEP</keyword>
  <keyword>Community setting</keyword>
  <keyword>point of care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sexually Transmitted Diseases</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

